<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="161391">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01831895</url>
  </required_header>
  <id_info>
    <org_study_id>CALM-FIM_US, CRD0152, G130013</org_study_id>
    <nct_id>NCT01831895</nct_id>
  </id_info>
  <brief_title>Controlling and Lowering Blood Pressure With The MOBIUSHD™</brief_title>
  <acronym>CALM-FIM_US</acronym>
  <official_title>CALM-FIM_US -Controlling and Lowering Blood Pressure With the MobiusHD™ - A Prospective Multicenter Safety Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vascular Dynamics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vascular Dynamics, Inc.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the safety and performance of the MobiusHD system in subjects with resistant
      hypertension.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open-label, multicenter, first-in-man clinical trial to be conducted inside the
      United States. Eligible subjects with stage 2 resistant systemic arterial hypertension
      currently being treated with a minimum of three (3) anti-hypertensive drugs, who consent to
      study participation will be assigned to treatment with the MobiusHD system.

      Potential study participants will be consented and then screened at two (2) baseline visits
      beginning at least 30 days prior to MobiusHD placement. Qualified patients will undergo
      placement of the MobiusHD under angiographic visualization, and will then be followed for 36
      months.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Anticipated">June 2016</completion_date>
  <primary_completion_date type="Anticipated">June 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Safety</measure>
    <time_frame>6 month</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Incidence of serious adverse events (SAEs) and unanticipated adverse device effects (UADE) reported for the study population from implantation through six (6) months of follow-up.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PERFORMANCE</measure>
    <time_frame>6 Months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Decrease in office cuff blood pressure (BP).</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>MobiusHD™</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MobiusHD™</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>MobiusHD™</intervention_name>
    <description>Implant that is placed in the carotid sinus to control hypertension.</description>
    <arm_group_label>MobiusHD™</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Office cuff SBP ≥ 160 mmHg measured per protocol instructions (Appendix IV) following
             at least one (1) month of maximally tolerated therapy with at least three (3)
             anti-hypertensive medications, of which at least one (1) must be a diuretic. Any
             combination medications will be counted per the active ingredient. (For example,
             Zestoretic (Lisinopril +HCTZ) equals two (2) anti-hypertensive medications)

        Exclusion Criteria:

          -  Known or clinically suspected baroreflex failure or autonomic neuropathy
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark C Bates, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>West Virginia University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sujith J Shetty, MBBS</last_name>
    <phone>650-963-9370</phone>
    <email>sshetty@vasculardynamics.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>El Camino Hospital</name>
      <address>
        <city>Mountain View</city>
        <state>California</state>
        <zip>94040</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eshwari Kovoor, M.B.B.S., CCRC</last_name>
      <phone>650-962-4466</phone>
      <email>eshwari_kovoor@Fogartyinstitute.org</email>
    </contact>
    <investigator>
      <last_name>James Joye, D.O.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UC Davis Vascular Center</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Margaret Norton, BSN</last_name>
      <phone>916-734-5671</phone>
      <email>margaret.norton@ucdmc.ucdavis.edu</email>
    </contact>
    <investigator>
      <last_name>John Laird, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30308</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Theresa Sanders, MN, RN</last_name>
      <phone>404-686-3872</phone>
    </contact>
    <investigator>
      <last_name>Chandan Devireddy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kate Dalton, MS, RD</last_name>
      <phone>212-342-1820</phone>
      <email>keb2114@cumc.columbia.edu</email>
    </contact>
    <investigator>
      <last_name>Ajay Kirtane, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Foundation</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adrienne Harvey</last_name>
      <email>harveya2@ccf.org</email>
    </contact>
    <contact_backup>
      <last_name>Tony Isabella</last_name>
      <email>isabelt@ccf.org</email>
    </contact_backup>
    <investigator>
      <last_name>Mehdi Shishehbor, D.O.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical College of Wisconsin - Froedtert Hospital</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emon Das, M.D.</last_name>
      <phone>414-805-2898</phone>
      <email>edas@mcw.edu</email>
    </contact>
    <investigator>
      <last_name>Osama O Zaidat, MD, MS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 28, 2014</lastchanged_date>
  <firstreceived_date>April 9, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hypertension</keyword>
  <keyword>Carotid Sinus</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
